Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma.

More than 80% of patients who undergo sentinel lymph node (SLN) biopsy have no nodal metastasis. In this discovery paper, we describe Merlin’s underlying model that combines clinicopathologic and molecular variables to identify patients with thin- and intermediate-thickness melanomas who may forgo the SLN biopsy procedure because of their low risk of nodal metastasis.

About this publication

This paper describes the essentials of Merlin Assay’s underlying CP-GEP algorithm:

  • CP-GEP’s variables and their weight in the algorithm;
  • The biological assertion of the genes involved;
  • The performance of CP-GEP including SLNB reduction rate.
Read full article

Stay in the loop for Falcon R&D Program updates

  • Receive Falcon-broad scientific and clinical updates
  • Receive invitations to collaborate in scientific or clinical research
  • Receive invitations to participate in scientific or clinical advisory boards
  • Receive invitations to participate in collaborative grant submissions
  • Receive notifications for Falcon Program events at conferences

Subscribe now

  • This field is for validation purposes and should be left unchanged.